You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

174 Results
Guidelines and Advice
Status: Current
Version: 1
Sep 2017
Cancer facts
Mar 2019
Guidelines and Advice
Status: Current
ID: 2016-2
Apr 2017
Guidelines and Advice
Status: Current
ID: pet 2017-1
Dec 2017
Guidelines and Advice
Status: Current
ID: PET 2017-2
Version: n/a
May 2018
Guidelines and Advice
Status: Current
ID: pet 2018-1
Version: n/a
Oct 2018
Guidelines and Advice
Status: Current
ID: PET 17
Jan 2017
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PANitumumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    pazopanib - For first-line treatment of advanced or metastatic renal cell carcinoma of clear cell histology in patients with good performance status (ECOG 0-1), with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pazopanib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Endocrine, 
Adrenal, 
Neuroendocrine, 
Pancreatic Neuroendocrine, 
Parathyroid, 
Thymoma, 
Thyroid, 
Gastrointestinal, 
Anus, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Gastrointestinal Stromal Tumours, 
Hepatobiliary / Liver / Bile Duct, 
Mesothelioma (Peritoneal), 
Neuroendocrine (GI), 
Pancreas, 
Rectal, 
Small bowel and appendix, 
Genitourinary, 
Bladder / Urothelial, 
Penile, 
Prostate, 
Renal cell / Kidney, 
Testis, 
Gynecologic, 
Cervix, 
Endometrial, 
Germ Cell, 
Gestational Trophoblastic Disease, 
Ovary, 
Uterine Sarcoma, 
Vagina, 
Vulva, 
Head and Neck, 
Larynx, 
Nasopharynx, 
Oral, 
Paranasal Sinus, 
Pharynx, 
Salivary Gland, 
Squamous Cell, 
Kaposi's Sarcoma, 
Lung, 
Mesothelioma (Pleural), 
Neuroendocrine (Lung), 
Non-Small Cell, 
Small Cell, 
Mesothelioma, 
Ocular / Eye, 
Sarcoma, 
Desmoid Tumour, 
Ewing's, 
Ewing's and Soft Tissue, 
GIST, 
Giant Cell Tumour, 
Kaposi's Sarcoma, 
Osteogenic / Bone, 
Soft Tissue, 
Uterine, 
Wilm's Tumour, 
Skin, 
Basal Cell, 
Melanoma, 
Merkel Cell, 
Squamous Cell, 
Unknown Primary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab (Adult and Pediatric) - Unresectable or Metastatic MSI-H or dMMR Advanced Solid Tumours
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pazopanib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab (Adult and Pediatric) - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV Melanoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024

Pages